By 2030, it is anticipated that the India HIV therapeutics market will reach a value of $389.90 Mn from $250.23 Mn in 2022, growing at a CAGR of 5.7% during 2022-2030. The market is primarily dominated by local players such as Cipla Limited, Aurobindo Pharma, and Hetero Drugs Limited. The market is driven by innovation in research and development, increasing prevalence, and good governance. The HIV therapeutics market in India is segmented by type, product, geography, end user, and distribution channel.
By 2030, it is anticipated that the India HIV therapeutics market will reach a value of $389.90 Mn from $250.23 Mn in 2022, growing at a CAGR of 5.7% during 2022-30.
The HIV/AIDS market in India is a significant one, as the country has one of the largest HIV-positive populations in the world. According to UNAIDS, there were approximately 2.1 Mn people living with HIV in India in 2019.
Overall, the estimated adult (15–49 years) HIV prevalence trend has been declining in India since the epidemic’s peak in 2000 and stabilizing in recent years. Over 2.4 Mn people with HIV are there in India as of 2021. National AIDS and STD Control Programme is being run in India to address HIV infection diagnosis and treatment in the country. In India, the cure for HIV infection is delivered in partnership with the community and NGOs.
Market Growth Drivers Analysis
In India, about 65% of people living with HIV are on ART, which gives scope to increase its use in the community. In India, the market is also likely to see an increased focus on research and development of new treatments and therapies for HIV/AIDS, as well as efforts to improve access to existing treatments.
India is the center of growth in the HIV therapeutics market, with a good CAGR of 5.7%, in contrast to the developed countries due to its high disease burden and low level of capital investment.
Market Restraints
Despite the government's efforts, access to HIV/AIDS treatment remains a challenge in India, particularly in rural and remote areas, and among marginalized populations such as men who have sex with men, people who inject drugs, sex workers, and transgender people.
Key Players
December 2022: Drugs for conditions like AIDS, TB, hypertension, infectious diseases, bacterial infections, and mental illness, among others, will be supplied to Saudi Arabia by Indian pharmaceutical companies. These important therapeutic areas have been covered as part of the 300 life-saving drugs list that the Saudi Food and Drugs Authority (SFDA), Kingdom of Saudi Arabia, shared with the Indian Drug Manufacturers Association (IDMA). The latter has invited Indian companies to supply drugs based on local requirements.
The National AIDS Control Organisation (NACO), established in 1992 is a division of India's Ministry of Health and Family Welfare that provides leadership to HIV/AIDS control programs in India through 35 HIV/AIDS Prevention and Control Societies and is "the nodal organization for the formulation of policy and implementation of programs for prevention and control of HIV/AIDS in India
Project SOCH has been created in India and is a beneficiary-centric web and mobile-based system, to track and record beneficiary service and inventory transactions in the National HIV Program to improve service delivery and beneficiary health outcomes. The treatment of HIV AIDS is free and has been since 2004 in India.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Types (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.